Genprex, Inc. (GNPX)
3.42
-0.09
(-2.56%)
USD |
NASDAQ |
Sep 03, 16:00
3.48
+0.06
(+1.75%)
After-Hours: 20:00
Genprex Net Income (Quarterly) : -4.447M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.447M |
| March 31, 2026 | -4.462M |
| December 31, 2025 | -3.790M |
| September 30, 2025 | -3.799M |
| June 30, 2025 | -4.675M |
| March 31, 2025 | -3.965M |
| December 31, 2024 | -4.330M |
| September 30, 2024 | -4.316M |
| June 30, 2024 | -6.496M |
| March 31, 2024 | -5.969M |
| December 31, 2023 | -5.929M |
| September 30, 2023 | -7.748M |
| June 30, 2023 | -7.980M |
| March 31, 2023 | -9.203M |
| December 31, 2022 | -6.766M |
| September 30, 2022 | -6.143M |
| June 30, 2022 | -5.765M |
| March 31, 2022 | -5.310M |
| December 31, 2021 | -5.682M |
| September 30, 2021 | -3.438M |
| Date | Value |
|---|---|
| June 30, 2021 | -3.986M |
| March 31, 2021 | -6.490M |
| December 31, 2020 | -5.228M |
| September 30, 2020 | -2.775M |
| June 30, 2020 | -4.373M |
| March 31, 2020 | -5.566M |
| December 31, 2019 | -2.425M |
| September 30, 2019 | -2.376M |
| June 30, 2019 | -3.695M |
| March 31, 2019 | -2.159M |
| December 31, 2018 | -3.431M |
| September 30, 2018 | -2.186M |
| June 30, 2018 | -6.061M |
| March 31, 2018 | -0.694M |
| December 31, 2017 | -0.6666M |
| September 30, 2017 | -0.7151M |
| June 30, 2017 | -1.181M |
| March 31, 2017 | -0.7513M |
| December 31, 2016 | -0.9991M |
| September 30, 2016 | -0.7199M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.447M |
| EPS Diluted (Quarterly) | -9.399 |
| Enterprise Value | -13.38M |
| Earnings Yield | -4.64K% |
| Normalized Earnings Yield | -4642.04 |